The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID‐19.

[1]  A. E. Eşkazan,et al.  COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single Center Survey from Turkey. , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[2]  C. de Ciuceis,et al.  Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19 , 2020, Cancer.

[3]  L. Baglietto,et al.  Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 , 2020, Frontiers in Oncology.

[4]  S. Başcı,et al.  Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[5]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[6]  C. Laprise,et al.  The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status , 2020, Journal of Infection and Public Health.

[7]  P. Westerweel,et al.  Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study , 2020, Leukemia.

[8]  R. Foà,et al.  Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey , 2020, Leukemia.

[9]  Q. Jiang,et al.  COVID-19 in persons with chronic myeloid leukaemia , 2020, Leukemia.

[10]  F. Pane,et al.  SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection , 2020, Mediterranean journal of hematology and infectious diseases.

[11]  Paolo Giudici,et al.  The Covid-19 pandemic in Italy , 2020 .

[12]  M. Krampera,et al.  Management of Chronic Myeloid Leukemia in Advanced Phase , 2019, Front. Oncol..

[13]  Martin C. Müller,et al.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.

[14]  M. Frieman,et al.  Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors , 2018, bioRxiv.

[15]  T. Brümmendorf,et al.  Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Amy Hughes,et al.  Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission , 2017, Front. Immunol..

[17]  Francisco Cervantes,et al.  Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia , 2017, The New England journal of medicine.

[18]  M. Frieman,et al.  Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion , 2016, Journal of Virology.

[19]  M. Baccarani,et al.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Flinn,et al.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.

[21]  E. Letsiou,et al.  Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. , 2015, American journal of physiology. Lung cellular and molecular physiology.